"目录号: HY-14185
GPCR/G Protein-
Lixivaptan (VPA-985, WAY-VPA 985) 是具有口服活性，选择性的vasopressin receptorV2 拮抗剂，对人和大鼠的IC50值分别为1.2 和 2.3 nM。
Vasopressin Receptor
相关产品
Conivaptan hydrochloride-Tolvaptan-Desmopressin Acetate-Mozavaptan-Terlipressin-WAY-151932-RO5028442-
生物活性
Description
Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selectivevasopressin receptorV2 antagonist, withIC50values of 1.2 and 2.3 nM for human and rat V2, respectively.
IC50& Target
IC50: 1.2 nM (human V2), 2.3 nM (rat V2)[1]
In Vitro
Lixivaptan displays competitive antagonist activity at V2 receptors[1].
In Vivo
In conscious dogs, water-loaded with 30 mL/kg (po) and arginine vasopressin (AVP)-treated (0.4 μg/kg in oil, sc), lixivaptan (1, 3, and 10 mg/kg po) increases Uvolover the AVP-treated vehicle group by 438, 1018, and 1133%, respectively, while Uosmdecreases from 1222 mOsm/kg (water-loaded and AVP treated vehicle) to 307, 221, and 175 mOsm/kg, respectively. In homozygous Brattleboro rats lacking AVP, lixivaptan at 10 mg/kg po (i.e., 10 times the dose producing V2 antagonist activity) b.i.d. for 5 days, shows a sustained antagonist action without evidence of agonist effects. In a randomized double-blind placebo-controlled ascending single dose study, patients (deprived of fluids overnight before dosing) are dosed orally with 30, 75, or 150 mg of lixivaptan. All three doses increase urine flow and serum sodium concentrations and produced significant dose-related decreases in urinary osmolality[1]. Phase II clinical trials in patients with congestive heart failure, liver cirrhosis with ascites or syndrome of inappropriate antidiuretic hormone have demonstrated that lixivaptan increases water clearance without affecting renal sodium excretion or activating the neurohormonal system[2].
References
[1].Albright JD, et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem. 1998 Jul 2;41(14):2442-4.
[2].Ghali JK, et al. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia. IDrugs. 2010 Nov;13(11):782-92.